| 2.25 0.03 (1.35%) | 07-26 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.87 | 1-year : | 3.35 |
| Resists | First : | 2.46 | Second : | 2.87 |
| Pivot price | 2.16 |
|||
| Supports | First : | 2.08 | Second : | 1.85 |
| MAs | MA(5) : | 2.23 |
MA(20) : | 2.12 |
| MA(100) : | 2.01 |
MA(250) : | 3.43  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 57.8 |
D(3) : | 60.6 |
| RSI | RSI(14): 53.8 |
|||
| 52-week | High : | 16 | Low : | 1.01 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ IBIO ] has closed below upper band by 33.6%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.27 - 2.28 | 2.28 - 2.29 |
| Low: | 2.18 - 2.19 | 2.19 - 2.2 |
| Close: | 2.23 - 2.25 | 2.25 - 2.26 |
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
Fri, 26 Jul 2024
iBio Inc. stock rises Friday, outperforms market - MarketWatch
Fri, 26 Jul 2024
iBio Updates CEO Employment Terms and Compensation Package - TipRanks
Fri, 26 Jul 2024
Brookline Capital Management Comments on iBio, Inc.’s FY2024 Earnings (NYSE:IBIO) - Defense World
Wed, 24 Jul 2024
iBio Inc. stock falls Wednesday, underperforms market - MarketWatch
Tue, 23 Jul 2024
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
Tue, 23 Jul 2024
iBio Inc. stock rises Tuesday, outperforms market - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
AMEX
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 1.4e+006 (%) |
| Held by Institutions | 0.7 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.563e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 206 % |
| Return on Equity (ttm) | -26.9 % |
| Qtrly Rev. Growth | 50000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -35 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.78 |
| Dividend | 0 |
| Forward Dividend | 90540 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|